The New Paper

June 8, 2021

FDA approves new Alzheimer's drug

The FDA granted accelerated approval for a new Alzheimer’s drug for the first time since 2003 yesterday, finding that the drug is “reasonably likely” to provide a clinical benefit. The drug (“Aduhelm”) has faced mixed feedback from the scientific community, with an FDA advisory panel recommending against approval last year.
This story is from the June 8, 2021 edition of The New Paper – a clear, concise daily briefing that makes fact-first news easy to consume. Try it today.